Francis Richard D sold $211K of TEVA
Francis Richard D (President and CEO) sold 6,153 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.35 ($0.21M total) on 2026-06-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This provides a fresh, auditable datapoint on insider activity, but the 10b5-1 designation typically limits inference about near-term fundamentals.
Market read
A new insider-selling datapoint for TEVA, likely to have only marginal trading impact absent other catalysts.
What to watch
Traders may overreact to insider selling; without accompanying operational/regulatory news, the signal is usually weak.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for TEVA, detailing an officer’s open-market sale under a pre-arranged 10b5-1 plan.
Ticker impact
SEC Form 4 shows TEVA CEO Francis Richard D sold 6,153 shares for ~$211.4K on a Rule 10b5-1 plan (open-market sale).
Low likelihood of a sustained price move solely from this disclosure; any reaction is likely brief unless accompanied by other catalysts.
The filing is a Form 4 insider transaction with explicit Rule 10b5-1 pre-arrangement, which reduces interpretive weight versus discretionary selling.
Market effects
No direct sector read-across; this is company-specific insider transaction disclosure.
None indicated beyond potential minor sentiment in US-listed TEVA.
None indicated; transaction is not tied to global operational developments in the text.
Counterpoint
Because the sale is explicitly under a Rule 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerTEVA
TEVA Pharmaceutical Industries Ltd; subject of the Form 4 insider sale disclosure.
- insiderFrancis Richard D
President and CEO; reported the sale of 6,153 shares.
